ACTRN12607000075482已完成3 期
A prospective, randomized, placebo-controlled, double-blind, cross-over study of the usefulness of sustained-release opioids in the subjective sensation of dyspnoea secondary to advanced disease with no reversible components in opioid naive patients.
Repatriation General Hospital0 个研究点目标入组 48 人开始时间: 2007年1月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •English speaking. Dyspnoea as a symptom for which no treatment is likely to modify course of disease.Renal function within 2 times of normal as measured by serum creatinine.Able to fill out diary cards.On stable oxygen needs.On stable medications.Willing and able to give informed consent.Both male and female are eligible.
排除标准
- •On other opioid medications. Confusion and/or obtundation.Uncontrolled nausea or vomiting. True adverse reaction(s) to previous opioidsKnown hypersensitivity to morphine, morphine salts or any of the capsule components.Acute or severe bronchial asthma.Respiratory depression.Gastrointestinal obstruction or biliary colic .Concomitant use of Monoamine Oxidase Inhibitor(s) (MAOIs) in the last 2 weeks.Pregnancy or breast feeding mothers.Past history of substance abuse.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)advanced hepatocellular carcinoma (HCC)EUCTR2020-004437-20-ITShanghai Junshi Biosciences Co., Ltd.519
进行中（未招募）
1 期
A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)EUCTR2020-004437-20-PLShanghai Junshi Biosciences Co., Ltd519
进行中（未招募）
1 期
A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndromeMarfan SyndromeEUCTR2010-019302-16-GBRoyal Brompton and Harefield NHS Foundation Trust490
进行中（未招募）
1 期
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin(R) in acute ischemic hemispehric stroke - CERE-LYSE-1EUCTR2004-001729-11-SKEBEWE Pharma GesmbH Nfg.KG
进行中（未招募）
不适用
A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke - CERE-LYSE-1Clinical diagnosis of ischemic stroke causing a measurable neurological deficitdefined as impairment of language, motor function, cognition and/or gaze,vision or neglect. Ischemic stroke is defined as an event characterised by thesudden onset of an acute focal neurologic deficit presumed to be due tocerebral ischemia after CT scan excludes haemorrhage. Onset of symptoms within 3 hours prior to initiation of rt-PA administrationMedDRA version: 6.0Level: LLTClassification code 10055221EUCTR2004-001729-11-SIEBEWE Pharma Ges.m.b.H Nfg.KG108